Pegfilgrastim Biosimilars Global Market Opportunities and Strategies to 2030: COVID 19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global pegfilgrastim biosimilars market.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the pegfilgrastim biosimilars market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global pegfilgrastim biosimilars market opportunities and strategies to 2030 report answers all these questions and many more.
The report covers the following chapters
Markets Covered: The global pegfilgrastim biosimilars market is segmented by -
Companies Mentioned: Coherus Biosciences Inc.; Biocon/Mylan; Sandoz
Countries: China, Japan, India, Australia, Indonesia, South Korea, USA, Brazil, UK, Germany, France, Russia.
Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Reasons to Purchase
- Outperform competitors using accurate up to date demand-side dynamics information.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Identify growth segments for investment.
- Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
- Create regional and country strategies on the basis of local data and analysis.
- Stay abreast of the latest customer and market research findings
- Benchmark performance against key competitors.
- Develop strategies based on likely future developments.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Gain a global perspective on the development of the market.
Description:
Where is the largest and fastest growing market for the pegfilgrastim biosimilars market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global pegfilgrastim biosimilars market opportunities and strategies to 2030 report answers all these questions and many more.
The report covers the following chapters
- Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
- Report Structure - This section gives the structure of the report and the information covered in the various sections.
- Introduction - The introduction section of the report gives brief introduction about segmentation by geography and segmentation by target antigen and by application.
- Market Characteristics - The market characteristics section of the report defines and explains the pegfilgrastim biosimilars market. This chapter includes different services covered in the report and basic definitions.
- Trends and Strategies - This chapter describes the major trends shaping the global pegfilgrastim biosimilars market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- COVID Impact Analysis - This section provides an insight on how the pandemic is impacting the pegfilgrastim biosimilars market.
- Global Market Size and Growth - This section contains the global historic (2015-2019) and forecast (2023F, 2025F, 2030F) market values, and drivers and restraints that support and restrain the growth of the market in the historic and forecast periods.
- Regional Analysis - This section contains the historic (2015-2019), forecast (2019-2023F, 2025F, 2030F) market value and growth and market share comparison by region.
- Market Segmentation - This section contains the market values (2015-2019, 2019-2023F, 2025F, 2030F) and analysis for segment by type in the market.
- Regional Market Size and Growth - This section contains the region’s market size (2019), historic and forecast (2015-2019, and 2023F, 2025F, 2030F) market values, and growth and market share comparison of major countries within the region. This report includes information on all the regions (Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa).
- Competitive Landscape - This section covers details on the competitive landscape of the global pegfilgrastim biosimilars market, estimated market shares and company profiles of the leading players.
- Key Mergers and Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Market Opportunities and Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Conclusions and Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for pegfilgrastim biosimilars companies in terms of product offerings, geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered: The global pegfilgrastim biosimilars market is segmented by -
- By Application: Chemotherapy Induced Neutropenia; Transplantation; Others
- By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Mail Order/ Online Pharmacies
Companies Mentioned: Coherus Biosciences Inc.; Biocon/Mylan; Sandoz
Countries: China, Japan, India, Australia, Indonesia, South Korea, USA, Brazil, UK, Germany, France, Russia.
Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
1. Pegfilgrastim Biosimilars Market Executive Summary2. Table of Contents3. List of Figures4. List of Tables5. Report Structure
6. Introduction
7. Pegfilgrastim Biosimilars Market Characteristics
8. Pegfilgrastim Biosimilars Market Trends and Strategies
9. Pegfilgrastim Biosimilars Market, COVID Impact Analysis
10. Global Pegfilgrastim Biosimilars Market Size and Growth
11. Global Pegfilgrastim Biosimilars Market Segmentation
12. Pegfilgrastim Biosimilars Market, Regional and Country Analysis
13. Asia-Pacific Pegfilgrastim Biosimilars Market
14. Western Europe Pegfilgrastim Biosimilars Market
15. Eastern Europe Pegfilgrastim Biosimilars Market
16. North America Pegfilgrastim Biosimilars Market
17. South America Pegfilgrastim Biosimilars Market
18. Middle East Pegfilgrastim Biosimilars Market
19. Africa Pegfilgrastim Biosimilars Market
20. Global Pegfilgrastim Biosimilars Market Competitive Landscape
21. Key Mergers and Acquisitions in The Pegfilgrastim Biosimilars Market
22. Pegfilgrastim Biosimilars Market Opportunities and Strategies
23. Pegfilgrastim Biosimilars Market, Conclusions and Recommendations
24. Appendix
Note: Product cover images may vary from those shown
The pegfilgrastim biosimilars market consist of sales of pegfilgrastim biosimilar drugs and related services. The drugs are used during the course of cancer treatment in order to reduce the infection risk for those patients undergoing immunosuppressant treatments, such as chemotherapy. The drug has further applications where protection from infections where immune system is compromised, such as in bone marrow transplants. It covers 2015 to 2019, termed the historic period, and 2019 to 2023 termed the forecast period, along with further forecasts for the periods 2023-2025 and 2025-2030.
The global pegfilgrastim biosimilars market reached a value of nearly $876.0 million in 2019. The market is expected to grow from $876.0 million in 2019 to $1,119.2million in 2023 at a rate of 6.3%. The growth is mainly due to an increased prevalence of cancer and increased adoption of the biosimilars. The market is expected to stabilize and reach $1,538.6 million in 2025 and $3,598.3 million in 2030.
Growth in the historic period resulted from government initiatives for biosimilars, increase in healthcare expenditure, and increase in pharmaceutical R&D expenditure and low costs of biosimilars. This growth was restricted by low rate of drug approvals, and lack of awareness on biosimilars among primary care physicians and specialists.
Going forward, aging population, increase in healthcare access and rising prevalence of chronic diseases are expected to drive the market. Effect of COVID-19, stringent regulations related to biosimilar approvals and prolonged production and approval time are major factors that could hinder the growth of the pegfilgrastim biosimilars market in the future.
The pegfilgrastim biosimilars market is segmented by application into chemotherapy induced neutropenia, transplantation and others. The chemotherapy induced neutropenia was the largest segment of the pegfilgrastim biosimilars market by application, accounting for 75.2% of the total market in 2019. Going forward, chemotherapy induced neutropenia segment is also expected to be the fastest growing segment in the pegfilgrastim biosimilar market, at a CAGR of 18.9%.
The pegfilgrastim biosimilars market is also segmented by distribution channel into hospital pharmacies, retail pharmacies and mail order/ online pharmacies. The hospital pharmacies was the largest segment of the pegfilgrastim biosimilars market by application, accounting for 89.8% of the total market in 2019. Going forward, the retail pharmacies segment is expected to be the fastest growing segment in the pegfilgrastim biosimilars market, at a CAGR of 30.4%.
North America was the largest region in the global pegfilgrastim biosimilars market, accounting for 51.1% of the total in 2019. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the pegfilgrastim biosimilars market will be Middle East and Asia Pacific, where growth will be at CAGRs of 34.8% and 30.3% respectively.
The pegfilgrastim biosimilars market is particularly prone to disruption from the coronavirus outbreak, as patients with cancer are more susceptible to viral infections, especially after chemotherapy, stem cell transplants, or surgeries thus preferring the biologic drug over the biosimilar.
The pegfilgrastim biosimilars market is concentrated, with a small number of large of large players in the market. Major players in the market include Coherus Biosciences Inc., Biocon/Mylan and Sandoz.
The top opportunities in the pegfilgrastim biosimilars market segmented by application will arise in the chemotherapy induced neutropenia segment, which will gain $194.2 million of global annual sales by 2023. The top opportunities in the pegfilgrastim biosimilars market segmented by distribution channel will arise in the hospital pharmacies segment, which will gain $127.6 million of global annual sales by 2023. The pegfilgrastim biosimilars market size will gain the most in the USA at $120.2 million.
Market-trend-based strategies for the pegfilgrastim biosimilars market include taking advantage of the less stringent regulations to develop new and improved biosimilars, investing extensively in R&D activities for the development of effective and innovative biologics, focusing on establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and increasing their focus on M&A growth strategies to expand the customer base and their geographic markets.. Player-adopted strategies in the pegfilgrastim biosimilars market include investing in expanding operations in different geographies, improving infrastructure and in acquisitions and mergers to strengthen their service offerings.
To take advantage of the opportunities, the publisher recommends the pegfilgrastim biosimilars companies to focus on strategic partnerships, focus on research & development, expand in emerging markets, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, provide competitively priced offerings in low-income countries to reach new users, companies should focus on creating awareness, and focus on creating awareness among patients and doctors.
The global pegfilgrastim biosimilars market reached a value of nearly $876.0 million in 2019. The market is expected to grow from $876.0 million in 2019 to $1,119.2million in 2023 at a rate of 6.3%. The growth is mainly due to an increased prevalence of cancer and increased adoption of the biosimilars. The market is expected to stabilize and reach $1,538.6 million in 2025 and $3,598.3 million in 2030.
Growth in the historic period resulted from government initiatives for biosimilars, increase in healthcare expenditure, and increase in pharmaceutical R&D expenditure and low costs of biosimilars. This growth was restricted by low rate of drug approvals, and lack of awareness on biosimilars among primary care physicians and specialists.
Going forward, aging population, increase in healthcare access and rising prevalence of chronic diseases are expected to drive the market. Effect of COVID-19, stringent regulations related to biosimilar approvals and prolonged production and approval time are major factors that could hinder the growth of the pegfilgrastim biosimilars market in the future.
The pegfilgrastim biosimilars market is segmented by application into chemotherapy induced neutropenia, transplantation and others. The chemotherapy induced neutropenia was the largest segment of the pegfilgrastim biosimilars market by application, accounting for 75.2% of the total market in 2019. Going forward, chemotherapy induced neutropenia segment is also expected to be the fastest growing segment in the pegfilgrastim biosimilar market, at a CAGR of 18.9%.
The pegfilgrastim biosimilars market is also segmented by distribution channel into hospital pharmacies, retail pharmacies and mail order/ online pharmacies. The hospital pharmacies was the largest segment of the pegfilgrastim biosimilars market by application, accounting for 89.8% of the total market in 2019. Going forward, the retail pharmacies segment is expected to be the fastest growing segment in the pegfilgrastim biosimilars market, at a CAGR of 30.4%.
North America was the largest region in the global pegfilgrastim biosimilars market, accounting for 51.1% of the total in 2019. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the pegfilgrastim biosimilars market will be Middle East and Asia Pacific, where growth will be at CAGRs of 34.8% and 30.3% respectively.
The pegfilgrastim biosimilars market is particularly prone to disruption from the coronavirus outbreak, as patients with cancer are more susceptible to viral infections, especially after chemotherapy, stem cell transplants, or surgeries thus preferring the biologic drug over the biosimilar.
The pegfilgrastim biosimilars market is concentrated, with a small number of large of large players in the market. Major players in the market include Coherus Biosciences Inc., Biocon/Mylan and Sandoz.
The top opportunities in the pegfilgrastim biosimilars market segmented by application will arise in the chemotherapy induced neutropenia segment, which will gain $194.2 million of global annual sales by 2023. The top opportunities in the pegfilgrastim biosimilars market segmented by distribution channel will arise in the hospital pharmacies segment, which will gain $127.6 million of global annual sales by 2023. The pegfilgrastim biosimilars market size will gain the most in the USA at $120.2 million.
Market-trend-based strategies for the pegfilgrastim biosimilars market include taking advantage of the less stringent regulations to develop new and improved biosimilars, investing extensively in R&D activities for the development of effective and innovative biologics, focusing on establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and increasing their focus on M&A growth strategies to expand the customer base and their geographic markets.. Player-adopted strategies in the pegfilgrastim biosimilars market include investing in expanding operations in different geographies, improving infrastructure and in acquisitions and mergers to strengthen their service offerings.
To take advantage of the opportunities, the publisher recommends the pegfilgrastim biosimilars companies to focus on strategic partnerships, focus on research & development, expand in emerging markets, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, provide competitively priced offerings in low-income countries to reach new users, companies should focus on creating awareness, and focus on creating awareness among patients and doctors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Coherus Biosciences Inc.
- Biocon/Mylan
- Sandoz
Note: Product cover images may vary from those shown
LOADING...
